The DOI matches its Crossref record.
Hepatitis C Treatment for Injection Drug Users: A Review of the Available Evidence
Abstract
Globally, approximately 90% of new hepatitis C infections are attributed to injection drug use, but there is a continuing reluctance to treat injection drug users (IDUs). There is evidence that a sizeable proportion of IDUs who begin hepatitis C treatment achieve a sustained virological response (SVR). In chronic hepatitis C treatment trials, the SVR rate among IDUs appears to be comparable to rates among non-IDUs; in trials prescribing pegylated interferon plus ribavirin, the median rate of SVR among IDUs was 54.3% (range, 18.1%-94.1%), compared with 54%-63% in the large treatment trials. Few trials of acute hepatitis C treatment report on outcomes in IDUs; however, among these trials, the SVR among IDUs was 68.5% (n=89), compared with 81.5% among non-IDUs (n=65). Additional studies are required to determine the optimal circumstances for treatment (e.g., enrollment in drug treatment, the requirement of a period of abstinence from injection drug use, or the establishment of multidisciplinary treatment programs).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., et al. (2013) · Hepatology · doi:10.1002/hep.26431 · Cited by 488
Self-citationBarua, S., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., & Taylor, L. E. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0406 · Cited by 401
The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations
Safreed-Harmon, K., Thursz, M., Dillon, J., El-Sayed, M., Elsharkawy, A., Hatzakis, A., Jadoul, M., Prestileo, T., Razavi, H., Rockstroh, J., et al. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1666841 · Cited by 257
Woolhouse, S., Cooper, E., & Pickard, A. (2013) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2013.05.018 · Cited by 30
Metadata
- Authors
- Hellard, M., Sacks‐Davis, R., & Gold, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08-15
- Volume
- 49
- Issue
- 4
- Pages
- 561-573
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101368910
- Cited by
- 232
- References
- 0
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatitis C Treatment for Injection Drug Users: A Review of the Available Evidence. https://app.cochat.ai/papers/10.1086/600304
- The paper
- Hellard, M., Sacks‐Davis, R., & Gold, J. (2009). Hepatitis C Treatment for Injection Drug Users: A Review of the Available Evidence. Clinical Infectious Diseases. https://doi.org/10.1086/600304
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
